通心络联合倍他乐克治疗冠心病心绞痛的Meta分析

摘要

Objective To objectively evaluate the efficacy and safety of tongxinluo combined with betaloc in treating coronary heart disease patients with angina.Methods Such databases as Cochrane Library,PubMed,Embase,PEDro,NTIS,Wangfang Database,CNKI and VIP Database were searched from their establishment to March 2016 for collecting the randomized controlled trials (RCTs) about tongxinluo combined with betaloc in treating coronary heart disease patients with stenocardia,and the references of those RCTs were also searched by hand.Two reviewers independently selected documents and extracted information according to the inclusion and exclusion criteria,having cross-checked and assessed methodological quality.Application of RevMan5.2 software evaluated the extracted dataes.Results Thirteen studies involving 1183 patients were included.The results of meta-analyses showed that compared with the control group,the curative effect of clinic and ECG of the observation group were significantly improved and the differences were statistically significant,but adverse reactions of both groups were not statistically significant.RR(95% CI)were respectively 1.34(1.26-1.42),1.23(1.15-1.32),0.64(0.28-1.46).Conclusion The clinical effect and EKG improvement are significantly improved after tongxinluo combined with betaloc in treating CHD patients with angina.%目的 评价通心络联合倍他乐克治疗冠心病心绞痛的临床疗效和安全性.方法 应用计算机检索Cochrane Library、PubMed、Embase、PEDro、NTIS、CNKI、VIP和万方数据库等电子数据库,查找所有通心络联合倍他乐克治疗冠心病心绞痛的随机对照试验(RCT),检索时限均为各数据库建库至2016年3月31日.由2名评价员按照纳入和排除标准独立选择文献并提取资料,交叉核对并进行方法学质量评估,应用RevMan5.2软件对所提取的数据进行Meta评价.结果 共纳入13个随机对照研究,1183例患者.Meta分析显示:与对照组相比,通心络联合倍他乐克组临床疗效、心电图改善效果显著提高,差异有统计学意义(P<0.05),但两组不良反应发生率差异无统计学意义(P>0.05).RR(95%CI)分别为1.34(1.26~1.42)、1.23(1.15~1.32)、0.64(0.28~1.46).结论 现有证据表明通心络和倍他乐克具有协同作用,能有效改善心脏供血,增加心肌细胞活力,降低复发率,显著提高临床症状疗效和心电图疗效,安全性较好.